This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: ##STR00001## wherein X, Y, and Z are O, S or NR.sup.5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.